SAB Total Assets from 2010 to 2024

SABS Stock

USD 3.03 0.10 3.19%

SAB Biotherapeutics Total Assets yearly trend continues to be comparatively stable with very little volatility. Total Assets will likely drop to about 63.5 M in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2010-12-31

Previous Quarter

83.9 M

Current Value

63.5 M

Quarterly Volatility

25 M

Credit Downgrade

Yuan Drop

Covid

Check SAB Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among SAB Biotherapeutics' main balance sheet or income statement drivers, such as Interest Income of 80.1 K, Depreciation And Amortization of 2.1 M or Interest Expense of 289.4 K, as well as many indicators such as Price To Sales Ratio of 16.12, Dividend Yield of 0.0 or PTB Ratio of 0.7. SAB financial statements analysis is a perfect complement when working with SAB Biotherapeutics Valuation or Volatility modules.

Check out the analysis of SAB Biotherapeutics Correlation against competitors.

For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.

Latest SAB Biotherapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of SAB Biotherapeutics over the last few years. Total assets refers to the total amount of SAB Biotherapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in SAB Biotherapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. SAB Biotherapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in SAB Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 83.94 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

SAB Total Assets Regression Statistics

	Arithmetic Mean	34,287,693
	Geometric Mean	27,708,797
	Coefficient Of Variation	73.02
	Mean Deviation	21,712,184
	Median	18,003,555
	Standard Deviation	25,036,639
	Sample Variance	626.8T
	Range	65.9M
	R-Value	0.79
	Mean Square Error	252.7T
	R-Squared	0.63
	Significance	0.0004
	Slope	4,428,070
	Total Sum of Squares	8775.7T

SAB Total Assets History

	2024	63.5 M
	2023	83.9 M
	2022	50.9 M
	2021	79.4 M
	2020	56.5 M

Other Fundumenentals of SAB Biotherapeutics

Intangibles To Total Assets

SAB Biotherapeutics Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Capital Surpluse	Deferred Long Term Liab	Treasury Stock
Total Assets		0.98	0.96	-0.87	-0.56	0.26	0.92	0.26	0.69	0.98	-0.86	0.99	-0.65	0.86	0.07	-0.38	0.98	0.64	0.7	-0.66	0.66
Total Stockholder Equity	0.98		0.97	-0.85	-0.57	0.3	0.9	0.32	0.54	1.0	-0.81	0.96	-0.64	0.86	0.17	-0.4	0.96	0.65	0.75	-0.71	0.68
Net Tangible Assets	0.96	0.97		-0.74	-0.41	0.48	0.86	0.47	0.55	0.97	-0.9	0.91	-0.48	0.77	-0.04	-0.22	0.98	0.5	0.61	-0.62	0.5
Net Debt	-0.87	-0.85	-0.74		0.86	0.2	-0.91	0.16	-0.64	-0.85	0.61	-0.89	0.94	-0.96	-0.39	0.72	-0.8	-0.91	-0.82	0.78	-0.88
Retained Earnings	-0.56	-0.57	-0.41	0.86		0.59	-0.74	0.54	-0.31	-0.58	0.18	-0.59	0.95	-0.78	-0.75	0.79	-0.47	-0.94	-0.9	0.88	-0.91
Accounts Payable	0.26	0.3	0.48	0.2	0.59		0.0	0.98	0.01	0.3	-0.56	0.2	0.49	-0.06	-0.66	0.5	0.36	-0.43	-0.29	0.25	-0.41
Long Term Debt	0.92	0.9	0.86	-0.91	-0.74	0.0		-0.02	0.65	0.9	-0.76	0.87	-0.75	0.83	0.22	-0.4	0.92	0.72	0.81	-0.85	0.68
Net Receivables	0.26	0.32	0.47	0.16	0.54	0.98	-0.02		-0.06	0.32	-0.51	0.22	0.42	0.01	-0.58	0.37	0.33	-0.34	-0.27	0.24	-0.33
Total Liab	0.69	0.54	0.55	-0.64	-0.31	0.01	0.65	-0.06		0.53	-0.72	0.69	-0.46	0.53	-0.29	-0.16	0.69	0.34	0.23	-0.21	0.31
Net Invested Capital	0.98	1.0	0.97	-0.85	-0.58	0.3	0.9	0.32	0.53		-0.8	0.96	-0.64	0.86	0.18	-0.4	0.96	0.66	0.76	-0.72	0.69
Short Long Term Debt	-0.86	-0.81	-0.9	0.61	0.18	-0.56	-0.76	-0.51	-0.72	-0.8		-0.79	0.31	-0.62	0.42	0.02	-0.92	-0.28	-0.3	0.38	-0.21
Total Current Assets	0.99	0.96	0.91	-0.89	-0.59	0.2	0.87	0.22	0.69	0.96	-0.79		-0.7	0.89	0.14	-0.48	0.94	0.69	0.7	-0.61	0.73
Capital Stock	-0.65	-0.64	-0.48	0.94	0.95	0.49	-0.75	0.42	-0.46	-0.64	0.31	-0.7		-0.9	-0.61	0.89	-0.55	-0.99	-0.81	0.76	-0.94
Net Working Capital	0.86	0.86	0.77	-0.96	-0.78	-0.06	0.83	0.01	0.53	0.86	-0.62	0.89	-0.9		0.35	-0.78	0.78	0.91	0.75	-0.71	0.86
Short Term Debt	0.07	0.17	-0.04	-0.39	-0.75	-0.66	0.22	-0.58	-0.29	0.18	0.42	0.14	-0.61	0.35		-0.66	-0.05	0.65	0.73	-0.61	0.74
Common Stock	-0.38	-0.4	-0.22	0.72	0.79	0.5	-0.4	0.37	-0.16	-0.4	0.02	-0.48	0.89	-0.78	-0.66		-0.23	-0.91	-0.59	0.5	-0.87
Property Plant Equipment	0.98	0.96	0.98	-0.8	-0.47	0.36	0.92	0.33	0.69	0.96	-0.92	0.94	-0.55	0.78	-0.05	-0.23		0.53	0.63	-0.64	0.53
Current Deferred Revenue	0.64	0.65	0.5	-0.91	-0.94	-0.43	0.72	-0.34	0.34	0.66	-0.28	0.69	-0.99	0.91	0.65	-0.91	0.53		0.83	-0.79	0.95
Capital Surpluse	0.7	0.75	0.61	-0.82	-0.9	-0.29	0.81	-0.27	0.23	0.76	-0.3	0.7	-0.81	0.75	0.73	-0.59	0.63	0.83		-0.95	0.88
Deferred Long Term Liab	-0.66	-0.71	-0.62	0.78	0.88	0.25	-0.85	0.24	-0.21	-0.72	0.38	-0.61	0.76	-0.71	-0.61	0.5	-0.64	-0.79	-0.95		-0.75
Treasury Stock	0.66	0.68	0.5	-0.88	-0.91	-0.41	0.68	-0.33	0.31	0.69	-0.21	0.73	-0.94	0.86	0.74	-0.87	0.53	0.95	0.88	-0.75

Click cells to compare fundamentals

About SAB Biotherapeutics Financial Statements

SAB Biotherapeutics shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although SAB Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in SAB Biotherapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on SAB Biotherapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

		Last Reported	Projected for Next Year
	Total Assets	83.9 M	63.5 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for SAB Stock Analysis

When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC